Park Avenue Securities LLC Has $622,000 Stock Position in Halozyme Therapeutics, Inc. $HALO

Park Avenue Securities LLC trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,959 shares of the biopharmaceutical company’s stock after selling 1,837 shares during the period. Park Avenue Securities LLC’s holdings in Halozyme Therapeutics were worth $622,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of HALO. Two Sigma Advisers LP acquired a new position in Halozyme Therapeutics in the 4th quarter worth about $282,000. GAMMA Investing LLC increased its position in Halozyme Therapeutics by 18,981.8% in the 1st quarter. GAMMA Investing LLC now owns 178,796 shares of the biopharmaceutical company’s stock worth $114,090,000 after purchasing an additional 177,859 shares during the last quarter. Parallel Advisors LLC increased its position in Halozyme Therapeutics by 12.5% in the 1st quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 208 shares during the last quarter. BTC Capital Management Inc. acquired a new position in Halozyme Therapeutics in the 1st quarter worth about $368,000. Finally, Rhumbline Advisers increased its position in Halozyme Therapeutics by 1.7% in the 1st quarter. Rhumbline Advisers now owns 417,430 shares of the biopharmaceutical company’s stock worth $26,636,000 after purchasing an additional 6,922 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $73.75 on Monday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a market cap of $8.63 billion, a price-to-earnings ratio of 16.88, a P/E/G ratio of 0.41 and a beta of 1.19. The business’s 50-day simple moving average is $68.98 and its 200-day simple moving average is $61.61. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the prior year, the company earned $0.91 EPS. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total transaction of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. This represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the sale, the director owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 86,227 shares of company stock worth $5,870,115 in the last 90 days. 2.90% of the stock is owned by company insiders.

Analyst Ratings Changes

HALO has been the topic of several research reports. The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price on the stock. Morgan Stanley upped their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, August 18th. Benchmark increased their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Finally, JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Hold” and a consensus target price of $69.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.